Evaluations of Unformulated and Formulated Dendrimer-Based Microbicide Candidates in Mouse and Guinea Pig Models of Genital Herpes

D. I. Bernstein, L. R. Stanberry, S. Sacks, N. K. Ayisi, Y. H. Gong, J. Ireland, R. J. Mumper, G. Holan, B. Matthews, T. McCarthy, Nigel Bourne

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Prevention of sexually transmitted infections is a priority in developed and developing countries. One approach to prevention is the use of topical microbicides, and one promising approach is the use of dendrimers, highly branched macromolecules synthesized from a polyfunctional core. Three new dendrimer products developed to provide stable and cost-efficient microbicides were initially evaluated in vitro for anti-herpes simplex virus activity and then in vivo by using a mouse model of genital herpes. From these experiments one product, SPL7013, was chosen for further evaluation to define the dose and duration of protection. Unformulated SPL7013 provided significant protection from genital herpes disease and infection at concentrations as low as 1 mg/ml and for at least 1 h following topical (intravaginal) administration of 10 mg/ml. This compound was then formulated into three vehicles and further evaluated in mouse and guinea pig models of genital herpes infection. In the murine evaluations each of the formulations provided significant protection at concentrations of 10 and 50 mg/ml. Formulated compounds provided protection for at least 1 h at a concentration of 10 mg/ml. From these experiments formulation 2V was chosen for dose ranging experiments using the guinea pig model of genital herpes. The guinea pig evaluations suggested that doses of 30 to 50 mg/ml were required for optimal protection. From these studies a lead compound and formulation (2V of SPL7013) was chosen for ongoing evaluations in primate models of simian immunodeficiency virus and Chlamydia trachomatis infection.

Original languageEnglish (US)
Pages (from-to)3784-3788
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume47
Issue number12
DOIs
StatePublished - Dec 2003

Fingerprint

Herpes Genitalis
Dendrimers
Anti-Infective Agents
Guinea Pigs
Intravaginal Administration
Topical Administration
Simian Immunodeficiency Virus
Chlamydia Infections
Local Anti-Infective Agents
Chlamydia trachomatis
Simplexvirus
Sexually Transmitted Diseases
Infection
Developed Countries
Primates
Developing Countries
Costs and Cost Analysis
SPL7013

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Evaluations of Unformulated and Formulated Dendrimer-Based Microbicide Candidates in Mouse and Guinea Pig Models of Genital Herpes. / Bernstein, D. I.; Stanberry, L. R.; Sacks, S.; Ayisi, N. K.; Gong, Y. H.; Ireland, J.; Mumper, R. J.; Holan, G.; Matthews, B.; McCarthy, T.; Bourne, Nigel.

In: Antimicrobial Agents and Chemotherapy, Vol. 47, No. 12, 12.2003, p. 3784-3788.

Research output: Contribution to journalArticle

Bernstein, DI, Stanberry, LR, Sacks, S, Ayisi, NK, Gong, YH, Ireland, J, Mumper, RJ, Holan, G, Matthews, B, McCarthy, T & Bourne, N 2003, 'Evaluations of Unformulated and Formulated Dendrimer-Based Microbicide Candidates in Mouse and Guinea Pig Models of Genital Herpes', Antimicrobial Agents and Chemotherapy, vol. 47, no. 12, pp. 3784-3788. https://doi.org/10.1128/AAC.47.12.3784-3788.2003
Bernstein, D. I. ; Stanberry, L. R. ; Sacks, S. ; Ayisi, N. K. ; Gong, Y. H. ; Ireland, J. ; Mumper, R. J. ; Holan, G. ; Matthews, B. ; McCarthy, T. ; Bourne, Nigel. / Evaluations of Unformulated and Formulated Dendrimer-Based Microbicide Candidates in Mouse and Guinea Pig Models of Genital Herpes. In: Antimicrobial Agents and Chemotherapy. 2003 ; Vol. 47, No. 12. pp. 3784-3788.
@article{4fdcef470f7d46b883949a95673582c5,
title = "Evaluations of Unformulated and Formulated Dendrimer-Based Microbicide Candidates in Mouse and Guinea Pig Models of Genital Herpes",
abstract = "Prevention of sexually transmitted infections is a priority in developed and developing countries. One approach to prevention is the use of topical microbicides, and one promising approach is the use of dendrimers, highly branched macromolecules synthesized from a polyfunctional core. Three new dendrimer products developed to provide stable and cost-efficient microbicides were initially evaluated in vitro for anti-herpes simplex virus activity and then in vivo by using a mouse model of genital herpes. From these experiments one product, SPL7013, was chosen for further evaluation to define the dose and duration of protection. Unformulated SPL7013 provided significant protection from genital herpes disease and infection at concentrations as low as 1 mg/ml and for at least 1 h following topical (intravaginal) administration of 10 mg/ml. This compound was then formulated into three vehicles and further evaluated in mouse and guinea pig models of genital herpes infection. In the murine evaluations each of the formulations provided significant protection at concentrations of 10 and 50 mg/ml. Formulated compounds provided protection for at least 1 h at a concentration of 10 mg/ml. From these experiments formulation 2V was chosen for dose ranging experiments using the guinea pig model of genital herpes. The guinea pig evaluations suggested that doses of 30 to 50 mg/ml were required for optimal protection. From these studies a lead compound and formulation (2V of SPL7013) was chosen for ongoing evaluations in primate models of simian immunodeficiency virus and Chlamydia trachomatis infection.",
author = "Bernstein, {D. I.} and Stanberry, {L. R.} and S. Sacks and Ayisi, {N. K.} and Gong, {Y. H.} and J. Ireland and Mumper, {R. J.} and G. Holan and B. Matthews and T. McCarthy and Nigel Bourne",
year = "2003",
month = "12",
doi = "10.1128/AAC.47.12.3784-3788.2003",
language = "English (US)",
volume = "47",
pages = "3784--3788",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Evaluations of Unformulated and Formulated Dendrimer-Based Microbicide Candidates in Mouse and Guinea Pig Models of Genital Herpes

AU - Bernstein, D. I.

AU - Stanberry, L. R.

AU - Sacks, S.

AU - Ayisi, N. K.

AU - Gong, Y. H.

AU - Ireland, J.

AU - Mumper, R. J.

AU - Holan, G.

AU - Matthews, B.

AU - McCarthy, T.

AU - Bourne, Nigel

PY - 2003/12

Y1 - 2003/12

N2 - Prevention of sexually transmitted infections is a priority in developed and developing countries. One approach to prevention is the use of topical microbicides, and one promising approach is the use of dendrimers, highly branched macromolecules synthesized from a polyfunctional core. Three new dendrimer products developed to provide stable and cost-efficient microbicides were initially evaluated in vitro for anti-herpes simplex virus activity and then in vivo by using a mouse model of genital herpes. From these experiments one product, SPL7013, was chosen for further evaluation to define the dose and duration of protection. Unformulated SPL7013 provided significant protection from genital herpes disease and infection at concentrations as low as 1 mg/ml and for at least 1 h following topical (intravaginal) administration of 10 mg/ml. This compound was then formulated into three vehicles and further evaluated in mouse and guinea pig models of genital herpes infection. In the murine evaluations each of the formulations provided significant protection at concentrations of 10 and 50 mg/ml. Formulated compounds provided protection for at least 1 h at a concentration of 10 mg/ml. From these experiments formulation 2V was chosen for dose ranging experiments using the guinea pig model of genital herpes. The guinea pig evaluations suggested that doses of 30 to 50 mg/ml were required for optimal protection. From these studies a lead compound and formulation (2V of SPL7013) was chosen for ongoing evaluations in primate models of simian immunodeficiency virus and Chlamydia trachomatis infection.

AB - Prevention of sexually transmitted infections is a priority in developed and developing countries. One approach to prevention is the use of topical microbicides, and one promising approach is the use of dendrimers, highly branched macromolecules synthesized from a polyfunctional core. Three new dendrimer products developed to provide stable and cost-efficient microbicides were initially evaluated in vitro for anti-herpes simplex virus activity and then in vivo by using a mouse model of genital herpes. From these experiments one product, SPL7013, was chosen for further evaluation to define the dose and duration of protection. Unformulated SPL7013 provided significant protection from genital herpes disease and infection at concentrations as low as 1 mg/ml and for at least 1 h following topical (intravaginal) administration of 10 mg/ml. This compound was then formulated into three vehicles and further evaluated in mouse and guinea pig models of genital herpes infection. In the murine evaluations each of the formulations provided significant protection at concentrations of 10 and 50 mg/ml. Formulated compounds provided protection for at least 1 h at a concentration of 10 mg/ml. From these experiments formulation 2V was chosen for dose ranging experiments using the guinea pig model of genital herpes. The guinea pig evaluations suggested that doses of 30 to 50 mg/ml were required for optimal protection. From these studies a lead compound and formulation (2V of SPL7013) was chosen for ongoing evaluations in primate models of simian immunodeficiency virus and Chlamydia trachomatis infection.

UR - http://www.scopus.com/inward/record.url?scp=10744228936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744228936&partnerID=8YFLogxK

U2 - 10.1128/AAC.47.12.3784-3788.2003

DO - 10.1128/AAC.47.12.3784-3788.2003

M3 - Article

VL - 47

SP - 3784

EP - 3788

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -